Nevirapine Approved

Nevirapine (Viramune(R)) received accelerated approval by the FDA on June 24, for use in adults in combination with other antiretrovirals. It is expected to be available in August. It is the first drug approved in a new class, the non-nucleoside reverse transcriptase inhibitors.

For more information about nevirapine, see our previous issue, AIDS TREATMENT NEWS #249, which reported on the recent FDA Antiviral Drugs Advisory Committee meeting which recommended approval. The actual approval came after our issue was published.